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il-12p35 inhibits neuroinflammation 
and ameliorates autoimmune 
encephalomyelitis
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Multiple sclerosis (MS) is an inflammatory demyelinating disease in which cytokines 
produced by immune cells that infiltrate the brain and spinal cord play a central role. 
We show here that the IL-12p35, the alpha subunit of IL-12 or IL-35 cytokine, might 
be an effective biologic for suppressing neuroinflammatory responses and ameliorating 
the pathology of experimental autoimmune encephalomyelitis (EAE), the mouse model 
of human MS. We further show that IL-12p35 conferred protection from neuropathy 
by inhibiting the expansion of pathogenic Th17 and Th1 cells and inhibiting trafficking 
of inflammatory cells into the brain and spinal cord. In addition, in  vitro exposure of 
encephalitogenic cells to IL-12p35 suppressed their capacity to induce EAE by adoptive 
transfer. Importantly, the IL-12p35-mediated expansion of Treg and Breg cells and its 
amelioration of EAE correlated with inhibition of cytokine-induced activation of STAT1/
STAT3 pathways. Moreover, IL-12p35 inhibited lymphocyte proliferation by suppressing 
the expressions of cell-cycle regulatory proteins. Taken together, these results suggest 
that IL-12p35 can be exploited as a novel biologic for treating central nervous system 
autoimmune diseases and offers the promise of ex vivo production of large amounts of 
Tregs and Bregs for immunotherapy.
Keywords: biologic, multiple sclerosis, experimental autoimmune encephalomyelitis, il-12p35, Breg cells, 
Treg cells, sTaTs, cytokine signaling
inTrODUcTiOn
Multiple sclerosis (MS) is a complex inflammatory demyelinating and degenerative disease thought 
to be triggered by blood-borne leukocytes that invade the central nervous system (CNS). These cells 
produce inflammatory cytokines such as IL-17 and IFN-γ that act on CNS-resident cells (microglia 
and astrocytes) to elicit production of additional cytokines (IL-1, IL-6, IL-12, IL-23, and TNF-α) 
and chemokines that promote further recruitment of leukocytes, which fuel the inflammatory 
cascade (1, 2). Besides the major histocompatibility complex loci, cytokines are among the most 
associated risk factor genes for MS and therefore a major target of disease-modifying therapies 
(immune suppressants, steroids, immune modulators, and biologics) for the treatment of MS (3). 
Abbreviations: MS, multiple sclerosis; EAE, experimental autoimmune encephalomyelitis; i35-Bregs, IL-35-producing regula-
tory B  cells; CNS, central nervous system; MOG35–55, myelin oligodendrocyte glycoprotein peptide 35–55; CFA, complete 
Freund’s adjuvant.
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Experimental autoimmune encephalomyelitis (EAE) is the pro-
totypical animal model of MS. Much of what we have learned 
about the pathophysiology of MS has come from EAE, which has 
also provided valuable insights into therapeutic approaches that 
might be effective in MS (4). EAE is based on the CNS-extrinsic/
peripheral pathogen-induced molecular mimicry model of MS 
etiology (5–7). Emulsified CNS antigen is administered along 
with complete Freund’s adjuvant (CFA) (immune stimulants). 
Autoreactive Th1 and Th17  cells activated at peripheral sites 
traffic from the draining lymph nodes, cross the blood–brain or 
blood–cerebrospinal fluid barrier and mediate CNS pathology 
(1, 4). The requirement of pathogen-associated molecular pat-
terns (PAMPs) contained in CFA for induction of EAE has led to 
interest in pathways that regulate cytokines elicited in response to 
PAMPs (8). Regarding potential biologics for MS, the IL-12/IL-6 
family of cytokines are of significant interest as they regulate the 
initiation, intensity, and duration of immune responses and are 
direct targets of TLR agonists present in CFA (8).
There are currently four known members of this family, IL-12, 
IL-23, IL-27, and IL-35 (9–12). Each member is composed of 
two subunits; an alpha subunit structurally similar to the IL-6 
superfamily cytokines (p19, p28, and p35) and a beta subunit 
homologous to type 1 cytokine receptors (p40 and Ebi3) (9). 
Published reports suggest that the predominant IL-12 family 
member produced within the environment of differentiating 
naïve lymphocytes significantly influences their developmental 
decisions and might therefore determine the lymphocyte subsets 
that would dominate the ensuing immune response (8). There 
is now consensus that IL-12 and IL-23 are pro-inflammatory 
while IL-35 is immune suppressive and a prime candidate as a 
biologic that can be used to suppress autoimmune diseases (9). 
That IL-35 is of critical importance in ameliorating CNS autoim-
mune diseases was demonstrated by several studies indicating 
that IL-35 can induce the expansion of Treg cells and a unique 
IL-35-producing regulatory B  cell (i35-Breg) population (9, 
13–15). However, isolating or producing sufficient quantities of 
the functional IL-35 heterodimeric cytokine has been challenging 
and very labor intensive (16, 17). Thus far, this has been a major 
impediment for ex vivo production of large scale IL-35-producing 
Bregs for adoptive Breg therapy.
An important question concerning the immunobiology of 
IL-35 relates to the relative contributions of IL-12p35 or Ebi3 
subunit to the biological function of IL-35. Specifically, it is unclear 
whether single chain IL-12p35 or Ebi3 also possesses intrinsic 
immune-regulatory activities that can be exploited therapeuti-
cally. In this study, we have produced and used recombinant 
IL-12p35 (rIL-12p35) to directly examine whether IL-12p35 
possesses some of the immune-suppressive activities attributed to 
IL-35 and if it can be used as a biologic to suppress EAE, thereby 
circumventing the arduous task of bioengineering functional 
recombinant heterodimeric IL-35 for use in Breg therapy.
MaTerials anD MeThODs
animals
Wild-type C57BL/6J mice were purchased from Jackson 
Laboratory. All protocols were approved by the NEI Animal 
Care and Use Committee and followed NIH guidelines for using 
animals in intramural research.
Production and characterization of Mouse 
ril-12p35 or p35
Mouse rIL-12p35 construct was generated by RT-PCR using 
forward primer: 5′-CGCGGATCCATTGGCCAGGGTCATTCC 
AGT-3′ and reverse primer: 5′-CCGCT CGAGGGCGGAGCTC 
AGATAG-3′. The IL-12p35 cDNA was cloned into the 3.6 kb pMIB 
vector containing an amino-terminal honeybee melittin (HBM) 
secretion signal sequence and a poly-histidine tag to facilitate 
isolation and characterization, and expression of the recombinant 
protein was driven by baculovirus immediate-early promoters of 
the polyhedrosis virus (Catalog # V8030-01; Invitrogen, Carlsbad, 
CA, USA). The expression construct was transfected into High 
Five insect cells, and stable transfectants were identified by drug 
selection (Blasticidin S; 100 µg/ml). To ensure that the recombinant 
clones expressed bona fide rIL-12p35, we isolated the expression 
vector (HBM-p35-Flag-His) from the stable clones and verified 
by DNA sequencing that no mutations were introduced during 
cloning or drug selection. The rIL-12p35 secreted in the insect 
cell culture was sequentially purified using Ni-NTA Purification 
system (Invitrogen), size-exclusion centricon filtration and two 
consecutive cycles of fast performance liquid chromatography 
(FPLC) gel filtration chromatography. The rIL-12p35 was further 
characterized by SDS-PAGE, Western blot/immunoprecipitation, 
and sedimentation equilibrium ultracentrifugation. Authenticity 
of the protein was confirmed by mass spectroscopy.
induction of eae
Experimental autoimmune encephalomyelitis was induced by 
subcutaneous immunization with 200 µg myelin oligodendrocyte 
glycoprotein peptide 35–55 (MOG35–55) (Sigma, St. Louis, MO, 
USA) in CFA emulsion, containing 2.5 mg/ml of heat killed, pul-
verized Mycobacterium tuberculosis strain H37RA. The mice also 
received two doses of 200 ng Bordetella pertussis toxin (Sigma, 
St. Louis, MO, USA) on day 0, and day 2 post-immunization 
intraperitoneally (i.p.) injection in 100 µl of RPMI 1640 medium 
containing 0.1% normal mouse serum. Some mice received p35 
(100 ng/mouse) concurrent with immunization with MOG and 
every other day until day 14 post-immunization. The control 
or p35-treated group (n =  12) was euthanized 21  days post-
immunization. The mice were monitored, and disease severity 
was assessed daily by a masked observer. Clinical signs of EAE 
were graded according to the following scale: 0, no clinical symp-
toms; 1, clumsiness, incontinence or atonic bladder, flaccid tail; 
2, mild paraparesis (trouble initiating movement); 3, moderate 
paraparesis (hind limb weakness); 4, complete front and hind 
limb paralysis; 5, moribund state (18). Spinal cord and brain were 
harvested 21 days post-immunization and stained with H&E. For 
adoptive transfer studies, mice with EAE were sacrificed on day 
17 post-immunization and used as donors in passive induction of 
EAE by adoptive transfer of encephalitogenic cells. Spleen and LN 
cells were isolated, stimulated with MOG35–55 peptide (20 µg/ml) 
for 3 days in the presence or absence of p35 and transferred i.v. to 
naive syngeneic recipient mice (10 × 106 cells/mouse; n = 12). Ten 
days after adoptive cell transfer, disease was assessed and brain or 
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spinal cord tissue was collected from recipient mice, fixed in 10% 
buffered formalin and sectioned for histopathological examina-
tion (18). CNS infiltrates were collected from the brain and spinal 
cord, and lymphocytes/mononuclear cells were isolated by percoll 
gradient for analysis.
In Vivo Model of lPs-induced 
inflammation
C57BL/6J mice were injected with LPS (15 μg/mouse), and some 
mice received p35 (100 ng/mouse) 1 h before LPS injection by i.p. 
route. The control or p35-treated group (n = 5) was euthanized 
96  h post-injection, and spleen cells were subjected to FACS 
analysis.
lymphocyte Proliferation assay
B cells were stimulated with LPS (1 µg/ml) while CD4+ T cells 
were cultured in plate-bound anti-CD3 antibody (Ab) (3  µg/
ml) and medium containing anti-CD28 Ab (1 µg/ml). B cells or 
T cells were propagated in presence or absence of p35. After 72 h, 
cultures were pulsed with 3H-thymidine (0.5 μCi/10 μl/well) as 
described previously (13). Presented data are mean CPM ± SEM 
of responses of five replicate cultures.
Detection of cytokine-expressing 
lymphocytes by Facs
Primary CD19+ B  cells (>98%) isolated from the spleen/LN 
(sorted for CD19+) were stimulated with LPS (1  µg/ml) for 
2 days. CD4+ T cells (>98%) from the spleen and/or LN were 
activated in plate-bound anti-CD3 Abs (3 µg/ml) and soluble 
anti-CD28 Abs (1  µg/ml) as described previously (13). For 
intracellular cytokine detection, cells were restimulated for 
5  h with PMA (20  ng/ml)/ionomycin (1  µM). GolgiStop was 
added in the last hour, and intracellular cytokine staining was 
performed using BD Biosciences Cytofix/Cytoperm kit as 
recommended (BD Pharmingen, San Diego, CA, USA). FACS 
analysis was performed on a MACSQuant analyzer (Miltenyi 
Biotec, San Diego, CA, USA) using protein-specific mono-
clonal antibodies and corresponding isotype control Abs (BD 
Pharmingen, San Diego, CA, USA) as described previously 
(13, 19). FACS analysis was performed on samples stained with 
mAbs conjugated with fluorescent dyes, and each experiment 
was color-compensated. Dead cells were stained with dead cell 
exclusion dye (Fixable Viability Dye eFluor® 450; eBioscience), 
and live cells were subjected to side scatter and forward scatter 
analysis. Quadrant gates were set using isotype controls with 
less than 0.2% background.
Western Blotting analysis
Preparation of whole cell lysates and performance of Western 
blot analysis were as described previously (20). Cell extracts 
(20–40  μg/lane) were fractionated on 4–12% gradient SDS-
PAGE, and antibodies used were: pSTAT1, pSTAT3, and pSTAT4 
(Cell Signaling Technology); IL-12p35, Ebi3, Cyclin E, cyclin D1, 
p27Kip1, and β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA). Pre-immune serum was used in parallel as controls, and 
signals were detected with HRP-conjugated secondary F(ab′)2 Ab 
(Zymed Laboratories) using the ECL-PLUS system (Amersham, 
Arlington Heights, IL, USA).
statistical analysis
Statistical analysis was performed by Student’s t-test (two-tailed). 
EAE scores were analyzed by nonparametric Mann–Whiney 
U test (two-tailed). Asterisks denote p value (*p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001).
resUlTs
il-12p35 (p35) reduces the  
severity of eae
The function of IL-12p35 in  vivo is unknown, and loss of 
IL-12p35 in mouse models of autoimmune disease has produced 
conflicting results. This is in part because IL-12p35 is a subunit of 
IL-12 and IL-35, two IL-12 family cytokines that exert opposite 
effects on inflammatory responses. While IL-12p35-deficient 
mice are protected against collagen-induced arthritis (21), these 
mice develop exacerbated EAE (22). In this study, we produced 
the mouse rIL-12p35 and used it to further investigate its potential 
in vivo functions and to examine whether it might possess intrin-
sic immune-suppressive effects that can be explored therapeuti-
cally. The rIL-12p35 was produced in insect cells, and the secreted 
protein was sequentially purified using Ni-NTA Purification 
system (Invitrogen), size-exclusion Centricon filtration, and two 
consecutive cycles of FPLC gel filtration chromatography (Figure 
S1 in Supplementary Material). The purified rIL-12p35 (p35) was 
characterized by SDS-PAGE, Western blot/immunoprecipita-
tion, and sedimentation equilibrium ultracentrifugation and was 
found to exhibit a molecular weight of ~27 kDa on reduced SDS 
gel (Figure S1 in Supplementary Material).
To directly examine whether p35 might possess immune-
suppressive activities in  vivo, we induced EAE in C57BL/6J 
mice by active immunization with MOG35–55 peptide in CFA and 
administered p35 concurrently with immunization as indicated 
in Figure 1A. Disease progression and severity were monitored 
as described in the Section “Materials and Methods.” Consistent 
with published reports, untreated mice developed severe EAE 
characterized by infiltration of inflammatory cells into the brain 
and spinal cord (Figure  1B), flaccid tail, paraparesis, complete 
front and hind limb paralysis, and/or moribund state. These hall-
mark features of encephalitis were much reduced in mice treated 
with p35, as indicated by the reduced disease score (Figure 1C). 
Analysis of histopathologic sections of the immunized mice 
revealed substantial infiltration of inflammatory cells into the 
spinal cord and brain of the untreated mice with EAE compared 
with a marked reduction of infiltrated inflammatory cells into 
these tissues of the p35 treatment group (Figure 1B).
The recruitment of IL-17-producing Th17  cells, IFN-γ-
expressing Th1 lymphocytes as well as several other inflam-
matory cells of the myeloid lineage into the brain and spinal 
cord are implicated in the immunopathogenic mechanisms 
that contribute to MS and EAE (22, 23). We therefore isolated 
cells from the brain and spinal cord and examined whether 
p35-reduced EAE severity correlated with a reduction of these 
FigUre 1 | IL-12p35 reduced the severity of experimental autoimmune encephalomyelitis (EAE) induced by active immunization with MOG35–55. (a) Schematic 
showing the treatment strategy. EAE was induced by immunization of C57BL/6J mice treated with MOG35–55-peptide in complete Freund’s adjuvant (CFA) (n = 12). 
Mice were treated by intraperitoneal injection of IL-12p35 (100 ng/mouse) or PBS on day 0 of immunization and every other day until day 12 post-immunization. (B) 
Representative photomicrographs of H&E stained sections of spinal cord and brain of mice on day 17 post-immunization (original magnification 200×). White arrows 
show inflammatory cells in the spinal cord or brain; black arrows denote inflammatory lesions in brain subpial location. (c) EAE clinical scores. (D–g) 
Characterization of immune responses on IL-12p35-treated EAE mice. Both spinal cord and brain cells were collected from individual mice, and the isolated cells 
were analyzed using FACS. The data are presented as the mean ± SEM of three determinations. ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05, significantly 
different from PBS-treated EAE.
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pathogenic lymphoid and myeloid cell types in the CNS. In line 
with our prediction, frequency of pathogenic Th17 and Th1 cells 
was significantly reduced in both the spinal cord and brain of 
p35-treated mice compared with untreated mice and interest-
ingly, this was accompanied by increase of IL-10-expressing 
CD4+ T cells (Figures 1D,E). In EAE, infiltrating CD4+ T cells 
are reactivated in the CNS by antigen-presenting cells, leading 
to exacerbation of the neuroinflammatory responses, enhanced 
production of inflammatory cytokines by microglia/astrocytes 
and further recruitment of monocytes into the CNS (2). Analysis 
of the brain and spinal cord revealed recruitment of inflam-
matory “monocyte-derived” myeloid cells characterized by 
CD11b+Ly6C+ phenotype, which were significantly reduced in 
the brain or spinal cord of the p35-treated mice (Figures 1F,G). 
Of note, these inflammatory monocyte-derived myeloid cells 
are rare in normal mice but increase during inflammation, 
and their disappearance correlates with disease resolution (24). 
Furthermore, diminished recruitment of the inflammatory cells 
into the brain or spinal cord of the p35-treated mice correlates 
with reduced expression of CXCR3 (Figures  1F,G), suggesting 
that p35 might mitigate EAE, in part, by suppressing trafficking 
of inflammatory cells into the CNS.
il-12p35 induces expansion of  
il-35-expressing Treg and Breg cells
The heterodimeric IL-35 cytokine, of which p35 is a subunit, 
has previously been shown to inhibit expansion of pathogenic 
Th17  cells and to play a critical role in mitigating autoimmune 
diseases by inducing expansion of IL-10 and/or IL-35-expressing 
Breg cells (13, 15). We therefore investigated whether suppression 
of pathogenic Th17 responses and amelioration of EAE mediated 
by p35 derived in part from inducing expansion of regulatory 
cells in the B cell compartment. Mice were immunized with the 
MOG35–55 peptide and treated with p35 or PBS. Control mice 
received CFA alone. Seventeen days post-immunization, cells 
harvested from the spleen of PBS-treated or p35-treated mice 
were restimulated in  vitro with MOG35–55 for 72  h. Intracellular 
FigUre 2 | IL-12p35 induces expansion of IL-35-expressing B cells in the spleen during experimental autoimmune encephalomyelitis (EAE). (a) EAE was induced 
in mice by active immunization with MOG35–55-peptide in complete Freund’s adjuvant, and the mice were treated with IL-12p35 or PBS. Spleen cells isolated from 
the mice on day 17 after EAE induction were restimulated ex vivo with MOG35–55 in presence or absence of IL-12p35 for 72 h and were analyzed by intracellular 
cytokine staining analysis (a) or lymphocyte proliferation assay (B). (a) For intracellular cytokine assay, cells were gated on CD19+ or CD4+ cells, and numbers in the 
quadrants indicate the percentages of T or B cells expressing IL-35 (p35 and Ebi3). The data are presented as the mean ± SEM of three determinations. 
****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05, significantly different from PBS-treated. (B) Proliferative responses assessed by 3H-thymidine incorporation 
assay were analyzed in five replicate cultures, and data presented as mean value of CPM of the five replicate cultures. Results represent at least three independent 
experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 [Student’s t-test (two-tailed)].
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cytokine staining revealed that p35-induced significant expansion 
of IL-35-producing B  cells in the spleen compared with PBS-
treated mice (Figure 2A; top panel). Surprisingly, we also observed 
significant expansion of IL-35-producing T cells in the spleen of 
the p35-treated mice (Figure 2A; lower panel). This observation is 
consistent with previous studies showing that IL-35 can induce the 
expansion of a regulatory T cell population that mediates immune 
suppression via IL-35 (25). Results of the lymphocyte proliferation 
assay further show that the increase of these regulatory lymphocyte 
subsets in the spleen of p35-treated mice correlates with suppres-
sion of MOG-specific encephalitogenic T cells (Figure 2B).
il-12p35 Promotes expansion of  
Treg cells in the Brain and spinal cord 
during eae
The observation that p35 can inhibit EAE induced by active 
immunization with MOG peptide/CFA was interesting, 
however, for targeted therapy, it was important to determine 
whether the capacity of encephalitogenic T cells to induce EAE 
is compromised in mice treated with p35. For this purpose, 
we isolated cells from the spleen and LN of mice with EAE 
or from EAE mice that were treated with p35. After in  vitro 
expansion with MOG peptide, 10 × 106 cells were transferred 
into naïve syngeneic mice, and the animals were monitored 
over 16  days for the development of EAE (as described in 
the Section “Material and Methods”). As indicated by the 
EAE clinical scores, cells derived from PBS-treated EAE mice 
efficiently transferred disease while mice that received cells 
from p35-treated EAE mice induced significantly milder 
disease (Figure  3A). Intracellular cytokine analysis of cells 
isolated from spinal cord and brain suggested that p35 sup-
pressed the capacity of pathogenic Th1 and Th17 cells to induce 
EAE by promoting the expansion of IL-10-producing T cells 
(Figures 3B,C). We also analyzed the effect of p35 treatment 
on encephalitogenic cells derived from the spleen and brain 
FigUre 3 | IL-12p35 treatment suppressed adoptive transfer of experimental autoimmune encephalomyelitis (EAE) by encephalitogenic T cells. EAE was induced in 
mice by active immunization with MOG35–55-peptide in complete Freund’s adjuvant, and the mice were treated with p35 or PBS. Spleen cells from the mice on day 
17 after EAE induction were restimulated ex vivo with MOG35–55 for 72 h. Activated cells (1 × 107 cells/mouse) were transferred to naïve syngeneic mice and clinical 
disease monitored until day 17 days after adoptive transfer of encephalitogenic cells. (a) EAE clinical scores. (B,c) On day 17 after adoptive transfer, cells were 
isolated from the brain or spinal cord and analyzed by intracellular cytokine staining. Cells were gated on CD4+ cells, and numbers in quadrants indicate percentage 
of cells IFN-γ-, IL-17-, and IL-10-expressing CD4+ T cells. (D) Proliferative responses of cells in the spinal cord and brain of C57BL/6J recipient mice 17 days after 
adoptive transfer were assessed by 3H-thymidine incorporation assay. Five replicate cultures were analyzed, and data presented as mean value of CPM of the five 
replicate cultures. The data are presented as the mean ± SEM of three determinations. ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05, significantly different 
from adoptive transfer of MOG35–55-stimulated with PBS.
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by lymphocyte proliferation assay. The data revealed that the 
increase of regulatory lymphocyte subsets in the spinal cord, 
brain, and spleen of the p35-treated mice was accompanied 
by significant suppression of MOG-specific encephalitogenic 
cells during EAE (Figure  3D). Taken together, these results 
suggest that in vivo exposure to p35 can be used to attenuate 
the pathogenic potential of encephalitogenic T cells, and that 
this might derive at least in part from the capacity of p35 to 
induce the expansion of IL-10-producing CD4+ T cells.
il-12p35 inhibits cytokine-induced sTaT 
Pathways and cell-cycle regulatory 
Proteins
Antigen-presenting dendritic cells (DCs) influence the differen-
tiation, proliferation, and effector functions of adaptive immune 
cells via secretion of cytokines such as IL-6 and/or IL-27. IL-6 
regulates T cells through activation of STAT3 (9, 26–30) whereas 
IL-27 regulates inflammation through activation of STAT1 
and STAT3 pathways (12). We therefore investigated whether, 
mechanistically, p35 might have mediated EAE by inhibiting 
cytokine-induced activation of STAT1 and STAT3 downstream 
of gp130, a common receptor utilized by both cytokines. CD4+ 
T  cells were isolated from C57BL/6J mice and stimulated for 
72 h in anti-CD3 coated plates (3 µg/ml) containing anti-CD28 
(1 µg/ml). After 72 h, the cells were starved for 2 h in serum-free 
medium containing 0.5% BSA and stimulated for 0–60 min in 
culture medium containing IL-6 or IL-27 (10 ng/ml). Western 
blot analysis revealed that unlike the heterodimeric IL-35, 
p35 could not activate the STAT1 or STAT3 pathway. Rather, 
it inhibited activation of both STAT1 and STAT3 pathways 
(Figures  4A,B). These observations are in line with a recent 
study showing that while IL-27p28 by itself could not activate 
the STAT pathway, it antagonized gp130-mediated signaling 
(31). Western blot analysis of the cells cultured for 3 days also 
revealed that p35 might also mediate its suppressive activities 
by antagonizing cell-cycle proteins that regulate lymphocyte 
proliferation (Figure  4C). Taken together, the p35-mediated 
suppression of pathogenic Th17  cells and its amelioration of 
EAE correlate with inhibition of cytokine-induced activation of 
STAT1/STAT3 pathways and perturbation of cell-cycle events 
that regulate lymphocyte expansion.
FigUre 4 | IL-12p35 inhibits STAT signaling pathway and cell-cycle regulatory proteins. (a,B) CD4+ T cells were stimulated in anti-CD3 coated plates and with 
anti-CD28 for 72 h. The cells were then washed, cultured in serum-free medium with p35 for 2 h, followed by stimulation with IL-6 or IL-27 for the indicated time 
periods. (c) Purified CD4+ T cells were TCR activated for 48 h as described earlier. Whole cell lysates were analyzed by Western blotting. Protein levels were 
normalized to total STAT or β-actin and quantified using Image-J software. Data are representative of at least three experiments.
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il-12p35 and il-35 activate Overlapping 
and Distinct immune-regulatory 
Mechanisms
Although the mechanism(s) by which IL-35 mediates its bio-
logical activities are not fully understood, data provided here 
suggest that IL-12p35 single chain subunit recapitulate some of 
the published immune-suppressive effects attributed to IL-35. 
However, there are mechanistic differences between IL-12p35 
and IL-35 heterodimeric cytokine that derive in part from the 
fact that IL-35 mediates its biological effects through activation 
of STAT1 and STAT3 while IL-12p35 could not activate these 
STAT pathways (Figure 4). Rather, IL-12p35 seems to function 
by antagonizing STAT pathways. Surprisingly, we have uncovered 
in this study two immune-regulatory molecules, LAG3 and IL-21 
receptor (IL-21R), that are differentially expressed by activated 
B cells in response to IL-35 or IL-12p35 stimulation (Figure 5). 
In response to in  vitro stimulation of sorted CD19+ B  cells in 
medium containing anti-CD40 and/or IL-35, we observed 
significant increase in the frequency of B cells expressing LAG3 
or IL-21R compared with cells cultured in medium containing 
anti-CD40 (Figure 5A). In contrast to the effects of IL-35 on the 
expression of LAG3 or IL-21R, culturing CD19+ B cells in medium 
containing anti-CD40 and p35 had no effect on the percentage of 
B cells expressing either protein (Figure 5B). We next examined 
whether these observations also pertain to B cells activated via 
T-independent pathway, such as by LPS. Similarly, activation of 
CD19+ cells with LPDS and/or p35 did not induce expansion 
of LAG3- and/or IL-21R-expressing B  cells, underscoring an 
additional difference that might contribute to differential effects 
of p35 and IL-35 on B cells (Figure 5C).
DiscUssiOn
There is increasing awareness that microorganisms and micro-
bial products might be important triggers for autoimmune and 
chronic inflammatory diseases. Thus, PAMPs that act through 
TLRs on DC lead to the production of pro-inflammatory IL-12 
family cytokines as well as suppressive members of the family that 
guard against excessive immune responses that cause autoim-
mune pathology. While these heterodimeric cytokines are under 
FigUre 5 | IL-35 but not IL-12p35 induces expansion of LAG3- and IL-21 receptor (IL-21R)-expressing B cells. (a) Sorted CD19+ B cells were cultured in the 
absence or presence of anti-CD40Ab (2 µg/ml) or anti-CD40 antibody (Ab) plus IL-35 (100 ng/ml) for 4 days. (B) Sorted CD19+ B cells were cultured in the absence 
or presence of anti-CD40Ab or anti-CD40 Ab plus p35 (100 ng/ml) for 4 days. The expression of LAG3 and IL-21R were analyzed with FACS. (c) Mice were injected 
with LPS (15 μg/mouse) via i.p. After 96 h, we analyzed the expression of LAG3 or IL-21R by FACS. The data are presented as the mean ± SEM of four 
determinations. ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05. Data are representative of at least three independent experiments.
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intense investigation, less attention has been given to the physi-
ological functions of the individual single chain proteins that are 
themselves differentially regulated by pathways downstream of 
distinct adaptor molecules that mediate transcriptional programs 
activated by TLRs.
In this study, we have shown that the IL-12p35 subunit protein 
possesses intrinsic immune-suppressive activities during EAE 
and can therefore be exploited as a biologic for the treatment of 
CNS autoimmune diseases. IL-12p35 suppressed lymphocyte 
proliferation, antagonized pathogenic Th17 responses, and 
ameliorated encephalitis in the EAE model by promoting the 
expansion of Tregs as well as IL-10- and IL-35-producing Breg 
cells in the brain and spinal cord. We further show that exposure 
of pathogenic encephalitogenic T cells to IL-12p35 rendered the 
cells partially anergic, resulting in diminished capacity to transfer 
EAE to naïve syngeneic mice. Importantly, IL-12p35 induced 
the expansion of IL-10-producing CD4+ T cells in the brain and 
spinal cord of mice treated with p35. Furthermore, the increases 
in regulatory cells in the brain or spinal cord correlated with 
decrease in the recruitment of Th17/Th1 cells and inflammatory 
myeloid cells into these tissues and lower EAE clinical scores. 
Thus, p35 treatment recapitulates some of the suppressive effects 
exhibited by IL-35 in CNS autoimmune diseases.
In context of the mechanism by which IL-12p35 mediates its 
immune-suppressive activities, we observed some mechanistic 
difference between IL-12p35 and the heterodimeric IL-35 
cytokine. While IL-35 mediates its biological effects through 
activation of STAT1, STAT4, and STAT3, IL-12p35 did not 
activate STAT proteins but instead antagonized STAT pathways 
induced by IL-6 and IL-27. These observations are reminiscent of 
observation reported for IL-27p28, one of the subunits of IL-27 
(29). IL-27p28, independently of Ebi3, antagonized cytokine 
signaling through gp130 (29). Notably, IL-27p28 treatment was 
able to inhibit pathogenic Th1 and Th17 responses and provide 
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protection from EAE as well as from experimental autoimmune 
uveitis, an autoimmune disease model that shares essential 
immunological mechanisms with EAE (31). Furthermore, mice 
transgenic for IL-27p28 expression exhibit defects in germinal 
center formation and Ab production, further supporting the 
notion that single chain IL-12 family cytokines might possess 
intrinsic anti-inflammatory activities that can be exploited 
therapeutically. Interestingly, the heterodimeric IL-27 (p28/
Ebi3) is thought exerts mostly anti-inflammatory roles in EAE 
through the induction of IL-10 in the CNS suggesting that the 
p35-mediated inhibition of IL-27 signaling may not completely 
explain the ability of p35 to ameliorate EAE and increase IL10. 
It is, however, of note that IL-27 can exert diametrically opposite 
effects on host immunity deriving from its differential effects on 
naïve and mature T cells: it promotes the differentiation of naive 
CD4+ T cells into pathogenic Th1 cells while suppressing produc-
tion of pro-inflammatory cytokines by mature CD4+ T-helper 
cells through the induction of IL-10. Discerning the physiologi-
cal effects of IL-27 is further complicated by the fact that IL-27 
activates both STAT1 and STAT3 in early activated CD4+ T cells 
while preferentially activating STAT3 in mature CD4+ T  cells. 
A consequence of p35-mediated suppression of IL-27-induced 
activation of STAT1 might be to antagonize the differentiation 
of naïve T cells into pathogenic Th1 cells during antigen prim-
ing while p35-mediated suppression of STAT3 activation might 
deprive the mature Th17 cell of a transcription factor required 
for its effector functions. Thus, p35-induced suppression of Th1 
and Th17 cells might in turn increase the frequency of Treg cells.
Another mechanistic difference between IL-12p35 and IL-35 
that might be of functional relevance is their differential capacity 
to induce the expansion of B  cells with upregulated expression 
of LAG3 and IL-21R. While IL-35 induced the expansion of 
B cells expressing LAG3 or IL-21R, IL-12p35 could not induce 
the expansion of B cells that express these important immune-reg-
ulatory proteins that mediate immune tolerance and lymphocyte 
development. Although increased expression of LAG3 on T cells 
is associated with immune suppression, additional studies are 
required to understand the functional implication of the upregu-
lation of LAG3 on B cells (32). Nonetheless, the data showing that 
IL-35 induced the expansion of B cells with increased expression 
of IL-21R is intriguing in view of a recent report that functional 
maturation of IL-10-secreting Breg cells requires IL-21-dependent 
cognate interactions between B and T cells (33).
Despite the significant excitement over the possibility of using 
IL-35 as a biologic for the treatment of autoimmune disease, its 
therapeutic use should be approached with caution because of the 
promiscuous chain pairing exhibited by IL-12 family cytokines. 
In addition, there is a dearth of pharmacokinetic data on the 
bioavailability of the IL-35 and the difficulty of ascertaining the 
stability IL-12p35:Ebi3 complex in  vivo. Unlike IL-12 or IL-23 
that are secreted as covalently bound heterodimer of IL-12p35:IL-
12p40 or IL-23p19:IL-12p40, the IL-12p35 and Ebi3 subunits are 
independently secreted and thought to eventually associate under 
physiological condition and form the stable IL-12p35:Ebi3 com-
plex that exhibits the immune-suppressive functions attributed to 
the heterodimeric IL-35 cytokine. Moreover, the factors that pro-
mote or regulate the formation and stability of the heterodimer are 
currently unknown. While prolonged maintenance of the stable 
IL-12p35:Ebi3 complex is desirable for treating an autoimmune 
disease, it also poses the risk of suppressing antitumor immune 
responses or compromising the efficacy of vaccines against infec-
tious diseases. The difficulty of predicting the immunological 
outcome of off-target pairing of either IL-12p35 or Ebi3 with 
other alpha/beta single IL-12 subunit proteins such as p19, p28, 
or p40 is also worrisome, as underscored by the recent discovery 
of IL-39, a novel pairing of Ebi3 and IL-23p19 that mediates pro-
inflammatory responses in Lupus-like mice (34). Despite the fact 
that similar concerns can also be raised for the use of IL-12p35, 
it should be borne in mind that other FDA approved biologics 
for treatment of MS, such as interferon beta-1b, interferon beta-
1a, natalizumab, alemtuzumab, fingolimod, or daclizumab are 
associated with adverse effects but are clinically beneficial if used 
judiciously. Nonetheless, ease in producing biologically active 
IL-12p35 and capacity of the p35 to induce regulatory T and B cells 
is unique, making IL-12p35 a particularly attractive biologics.
In summary, we have found that IL-35-producing T and B cells 
are critical regulators of autoimmune and infectious diseases, and 
that IL-35 can convert human/mouse T and B  cells into Tregs 
and Bregs, respectively. However, production of large amounts of 
biologically active IL-35 for therapeutic use is difficult and labor 
intensive, thus providing the major impetus to examine whether 
the IL-12p35 subunit can recapitulate some of the immunosup-
pressive activities of IL-35. Discovery that IL-12p35 can also 
induce IL-10 or IL-35-producing Treg/Breg cells offers the 
promise of Treg and Breg immunotherapy and would facilitate 
investigations on the role of i35-Bregs and iTR35 cells in autoim-
mune diseases and cancer.
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FigUre s1 | Schematic representation of the cDNA construct used to produce 
the recombinant IL-12p35 (p35) protein in insect cells. (a) HBM, honeybee 
melittin secretion signal; FLAG and HIS are tags used to facilitate the isolation 
and purification of the p35 protein. (B,c) Characterization of the p35 protein 
following two sequential purification cycles on fast performance liquid 
chromatography columns. (D) Western blot analysis of the purified p35 protein.
